

# **Chloroform associated with bone mineral density and bone mineral content in adults: a population-based cross-sectional research.**

1 **Lin Li<sup>1¶</sup>, XK Liu<sup>2¶</sup>, Xia Zhang<sup>3¶</sup>, Yan Zhang<sup>3¶</sup>, Qing Li<sup>3¶</sup>, HF Geng<sup>2</sup>, Li Shi<sup>2</sup>, Ben**  
2 **Wang<sup>2</sup>, QQ Qiu<sup>2</sup>, TP Yu<sup>2</sup>, YQ Sang<sup>2</sup>, LY Wang<sup>2</sup>, Wei Xu<sup>2\*</sup>, Jun Liang<sup>1, 2\*</sup>**

3 <sup>1</sup>Graduate School of Bengbu Medical College, Bengbu, Anhui, China.

4 <sup>2</sup>Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Institute of Medical  
5 Sciences, Xuzhou Clinical School of Nanjing Medical University, Affiliated Hospital  
6 of Medical School of Southeast University, Jiangsu, China.

7 <sup>3</sup>Xuzhou Medical University, Xuzhou, Jiangsu, China.

## **First-author:**

9 Lin Li, email: 1621561732@qq.com

## **Co-authors:**

11 XK Liu, email: liuxuekui314@126.com

12 Xia Zhang, email: garnele99@163.com

13 Yan Zhang, email: zhangyan202103@126.com

14 Qing Li, email: 769798497@qq.com

15 HF Geng, email: genghoufa@njmu.edu.cn

16 Li Shi, email: shili2006\_2009@126.com

17 Ben Wang, email: wangben1210@126.com

18 QQ Qiu, email: qq18796249070@163.com

19 TP Yu, email: yutianpei1188@163.com

20 YQ Sang, email: sangyiquan86@163.com

21 LY Wang, email: 786773733@qq.com

22 <sup>¶</sup>These authors contributed equally to this work.

## **\* Correspondence:**

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

- 24 Jun Liang, email: [mwlj521@njmu.edu.cn](mailto:mwlj521@njmu.edu.cn)
- 25 Wei Xu, email: [weixu159357@njmu.edu.cn](mailto:weixu159357@njmu.edu.cn)

## 26 **Abstract**

27 **Background:** According to a recent cross-sectional study, reduced Bone Mineral  
28 Density (BMD) in U.S. adults is associated with co-exposure to several Volatile  
29 Organic Compounds (VOCs), and contact with VOCs increases the risk of developing  
30 osteoporosis. However, the relationship between chloroform (an essential VOC  
31 component) and BMD remains unclear. Consequently, we aimed to explore the  
32 relationship between chloroform alone and Bone Mineral Density or Bone Mineral  
33 Content (BMD or BMC).

34 **Methods:** Herein, 2,553 individuals aged 18 and above from the National Health  
35 and Nutrition Examination Surveys (NHANES) in 2009-2010, 2013-2014, and 2017-  
36 2020, were included. We employed two independent t-tests and multi-linear regression  
37 models to statistically assess the relationship between chloroform exposure and  
38 BMD/BMC in the spine and femoral area.

39 **Results:** A "V"-shaped correlation between chloroform exposure and BMD/BMC  
40 was observed in the unadjusted model, particularly in the Ward's triangle and femoral  
41 neck as a whole. A negative correlation was specifically observed for the Ward's  
42 triangle BMD/BMC and L4 BMD/BMC. On the other hand, in the adjusted model, a  
43 dominantly negative correlation between the L4 BMC and chloroform exposure was  
44 observed over a range of exposure levels. The subgroup analysis revealed a negative  
45 correlation between chloroform concentrations and BMC in the femur and spine,  
46 especially in women and the 65-80 age population.

47 **Conclusion:** Our study revealed a "V" shaped correlation between chloroform and  
48 BMD/BMC of the femur and spine in U.S. adults. This finding highlights the fact that  
49 prolonged exposure to chloroform may increase the risk of developing osteoporosis.

## 50 **Introduction:**

51 Osteoporosis is a frequent bone disease characterized by reduced bone volume,  
52 microstructural degeneration, and fragility fractures [1]. Fragility fractures, particularly  
53 in the most vulnerable areas, including the vertebrae, hip, and forearm, are one of the  
54 severe complications of osteoporosis. According to reports [2,3], fragility fractures can  
55 cause emotional distress, reduced quality of life, and an increased socioeconomic  
56 burden. Approximately 79,000 people in the United Kingdom suffer hip fractures  
57 annually, with the cost in 2010 estimated at £3.5 billion and expected to rise to £5.5  
58 billion each year by 2025, implying that osteoporosis will be a significant challenge in  
59 the future and its burden on the medical community must be removed [4]. According  
60 to osteoporosis research, enhancing Bone Mineral Density (BMD) is closely linked to  
61 decreasing the risk of vertebral and non-vertebral fractures [5]. Many factors, including  
62 aging, femininity, estrogen metabolism disturbances, and physical inactivity, are  
63 critical in lowering BMD and have been implicated in the pathogenesis of osteoporosis  
64 [6,7].

65 People are frequently exposed to Volatile Organic Compounds (VOCs) such as  
66 chloroform, bromoform, dibromochloromethane, and dichlorobromomethane. The  
67 increased contact is due to the widespread use of disinfectants, as these VOCs are  
68 produced when disinfectants react with organic substances in water sources [8, 9, 10].

69 Compared to normal mice, the U.S. National Toxicology Program noted an increased  
70 incidence of sternal dysplasia in bromoform-exposed mice [11]. Other studies  
71 discovered a connection between VOC exposure and bone-healing-related chemokines,  
72 with a downregulated osteoblast chemokine CXCL12 expression after exposure to  
73 benzene or its derivatives, and that CCL2 (a chemokine essential for osteoclast  
74 formation) production was induced by chlorobenzene exposure [12, 13, 14]. These  
75 findings imply that VOCs could impact BMD levels by affecting osteoblast activity.  
76 Additionally, individual and combined VOC exposure was found to be associated with  
77 lower BMD in U.S. adults, and Alkaline Phosphatase (ALP), Body Mass Index (BMI),  
78 Fasting Insulin (F.I.), and High-Density Lipoprotein (HDL) were shown to be  
79 intermediaries in VOC and BMD co-exposure [15]. Chloroform, a significant member  
80 of VOCs, is strongly absorbed through the pulmonary, oral, and dermal pathways and  
81 is linked with several acute and chronic illnesses, including neurological, respiratory,  
82 hepatic, and renal dysfunctions, reproductive abnormalities, and digestive or urinary  
83 malignancies [16, 17]. However, the connection between blood chloroform and  
84 BMD/BMC was rarely investigated alone in past studies.

85 This research aimed to explore the relationship between blood chloroform and  
86 BMD/BMC using data from the National Health and Nutrition Examination Survey  
87 (NHANES). We, therefore, obtained femur BMD/BMC and spine BMD/BMC datasets  
88 published in 2009-2010, 2013-2014, and 2017-2020 from NHANES.

## 89 **Materials and methods**

## 90 **Study design and participants**

91 Herein, data from the NHANES, a cross-sectional survey of more than 5,000  
92 respondents conducted yearly by the Center for Disease Control and Prevention's (CDC)  
93 Center for Health Statistics, was used. We specifically used NHANES data from 2009-  
94 2010, 2013-2014, and 2017-2020. We selected 22,333 adults (of whom 6,227 had blood  
95 chloroform data) from 36,272 available subjects. Subsequently, 2637 individuals with  
96 femur and spine Dual-Energy X-ray Absorptiometry (DEXA) data were selected. After  
97 excluding patients with a history of osteoporosis treatment, 2553 subjects aged  $\geq 18$   
98 years were included in the final statistical analysis. **Fig1** depicts the flowchart for  
99 participant exclusion. (**Fig1**: Flowchart for Screening Research Subjects)

## 100 **Variables**

101 In this study, we used blood chloroform concentration as the exposure variable.  
102 Chloroform concentration in the blood was analyzed using Capillary Gas  
103 Chromatography (G.C.) and Mass Spectrometry (M.S.) with Selected Ion Monitoring  
104 (SIM) detection and isotope dilution. The chloroform detection limits ranged from  
105 0.00148 to 0.602 ng/ml, and for lower LLOD (Lower Limit of Detection) values, an  
106 interpolated LLOD value divided by the square root of 2 was used. The dependent  
107 variables were the femoral and spinal Bone Mineral Density (BMD) and Bone Mineral  
108 Content (BMC). In Shepherd's laboratory, Dual-Energy X-ray Absorptiometry (DXA)  
109 was used to measure the spine and femur BMC, whereas the Hologic software APEX  
110 v4.0 (Hologic) sector beam densitometry was used to scan and calculate the spine and  
111 femur BMC and BMD. All variables included as covariates in the study are listed below:

112 Gender (male, female), Race/ethnicity (Mexican-American, Non-Hispanic white, Non-  
113 Hispanic black, other Hispanic, other race), Household Poverty-Income Ratio (PIR by  
114 poverty line: values 0 to 0.99 indicate below poverty,  $\geq 1.00$  indicate poverty or above  
115 poverty)[18], Excessive alcohol consumption ( $>1$  drink /day for women or  $>2$  drinks  
116 /day for men (in the past 12 months)), Hypertension (blood pressure  $\geq 140/90$  mmHg or  
117 taking anti-hypertensive medication), Diabetes mellitus (self-reported diabetes history,  
118 Fasting Blood Glucose (FPG) level  $\geq 7.0$  mmol/L, HbA1c  $\geq 6.5\%$  or taking anti-diabetic  
119 medication), Arthritis, Cardiovascular disease (self-reported congestive heart failure,  
120 coronary artery disease, heart attack or stroke history), Thyroid problems (self-reported  
121 hyperthyroidism, hypothyroidism, thyroiditis), COPD(Chronic Obstructive Pulmonary  
122 Disease), Smoking (self-described as having smoked  $\geq 100$  cigarettes in a lifetime),  
123 History of osteoporosis treatment and osteopenia (Bone Mineral Density (BMD) T-  
124 score  $\leq -2.5$  in lumbar spine or femoral neck) [19]. Age, body weight, abdominal  
125 circumference, and BMI were all continuous covariates in our analysis. The blood  
126 chloroform, BMD, BMC, and covariance data were obtained from the NHANES  
127 website.

## 128 **Statistical analysis**

129 Statistical analyses were conducted using R software (version 3.6.1), IBM SPSS  
130 version 25(IBM, Armonk, New York, USA), and GraphPad Prism9. The mean and  
131 Standard Deviation (S.D.) values were used for variables with continuous features,  
132 whereas categorical variable represented frequency. The Spearman correlation test  
133 was used to assess differences between the classification variables in the exposure

134 group. The Kruskal-Wallis test or one-way ANOVA was used to examine differences  
135 in continuous variables between groups. Blood chloroform levels were grouped into  
136 tertiles (tertile 1: <33%, tertile 2: 33-66%, tertile 3: >66%) and univariate and  
137 multivariate linear regression models were tested to analyze the relationship between  
138 the different blood chloroform categories. We adjusted the confounding variables in  
139 the multi-linear regression model to investigate the correlation between blood  
140 chloroform levels and BMD/BMC (femoral and spine). These included Model 1 (the  
141 unprecedented model), Model 2 (for gender, age, race, and BMI adjustment), and  
142 Model 3 (for gender, age, race, BMI, osteoporosis, COPD, and thyroid problems  
143 adjustments, and further adjustment for arthritis, smoking and excessive drinking).  
144 Regression analysis results were expressed as  $\beta$  (beta) coefficients, 95% confidence  
145 intervals, and statistically significant P values (P values<0.05).

## 146 **Results**

### 147 **Subjects characteristics**

148 This study had 2553 participants (1288 women and 1265 men). Based on the femoral  
149 and spinal DEXA data, the average age of the participants and the average chloroform  
150 levels in their whole blood was 48.83 years and  $0.0171 \pm 0.0182$  ng/mL (ranging from  
151 0.0021 to 0.1790 ng/mL), respectively. The weighted characteristics of these  
152 participants based on the third-class classification are shown in **TableS1**. According to  
153 the femoral and spine DEXA data, differences among groups in baseline variables such  
154 as age, race, height, BMI, waist circumference, hypertension, arthritis, thyroid illnesses,  
155 and smoking were statistically significant (P<0.05).



## 156 **Connection between chloroform and BMD**

157 **Tables1-2** and **S2** illustrate the results. Blood chloroform concentration by tertile had  
158 a statistically significant relationship with total femoral BMD ( $P < 0.05$ ); femoral neck  
159 BMD ( $P < 0.01$ ); rotor BMD ( $P < 0.05$ ); inter-rotor BMD ( $P < 0.05$ ); Ward's triangle  
160 BMD ( $P < 0.01$ ); and L4 BMD ( $P < 0.01$ ).

161 The multiple linear regression models and weighted univariate analyses are  
162 detailed in **Tables1-2**. All regressions were conducted before adjusting for some of the  
163 covariates (model 1), except for total spine BMD ( $\beta$  -0.0020; 95% CI -0.0051, 0.0011),  
164 L1 BMD ( $\beta$  0.0004; 95% CI -0.0030, 0.0039), L2 BMD ( $\beta$  - 0.0024; 95% CI -0.0057,  
165 0.0009), and L3 BMD ( $\beta$  -0.0016; 95% CI -0.0048, 0.0016). A statistically significant  
166 correlation existed between increased blood chloroform concentration and total femoral  
167 BMD, femoral neck BMD, rotor BMD, inter-rotor BMD, Ward's triangle BMD, and  
168 L4 BMD ( $P < 0.05$ ). The L4 BMD was negatively correlated with blood chloroform  
169 levels after adjusting for some covariates (model 2). After adjusting for more relevant  
170 covariates simultaneously (model 3), L4 BMD decreased with rising blood chloroform  
171 levels, but not at other sites.

**Table1: The relationship between blood chloroform and BMD/BMC in the femur**

	Chloroform (ng/mL)	Model1 β(95%CI) value	Model2 β(95%CI) P value	Model3 β(95%CI) P value
Total femur BMD(g/cm2) *	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0014(-0.0054,0.0083)0.681	0.0043(-0.0012,0.0098)0.123	0.0047(-0.0007,0.0102)0.090
	Q3 : 0.01700-0.17900ng/ml	-0.0082(-0.0150,-0.0014)0.019	Reference	-0.0029(-0.0084,0.0026)0.308
Total femur BMC(g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0034(-0.0075,0.0144)0.542	0.0021(-0.0052,0.0094)0.574	0.0024(-0.0049,0.0097)0.520
	Q3 : 0.01700-0.17900ng/ml	-0.0142(-0.0252,-0.0033)0.011	-0.0060(-0.0133,0.0014)0.112	-0.0064(-0.0138,0.0009)0.087
Femoral neck BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	-0.0071(-0.0148,0.0005)0.070	-0.0005(-0.0066,0.0056)0.876	-0.0001(-0.0062,0.0060)0.983
	Q3 : 0.01700-0.17900ng/ml	-0.0089(-0.0166,-0.0012)0.024	-0.0004(-0.0066,0.0057)0.889	-0.0011(-0.0073,0.0050)0.714
Femoral neck BMC(g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	-0.0055(-0.0147,0.0037)0.238	-0.0009(-0.0076,0.0058)0.789	-0.0006(-0.0073,0.0061)0.871
	Q3 : 0.01700-0.17900ng/ml	-0.0142(-0.0233,-0.0051)0.002	-0.0040(-0.0107,0.0028)0.249	-0.0046(-0.0113,0.0021)0.182
Trochanter BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0031(-0.0043,0.0106)0.411	0.0055(-0.0008,0.0119)0.089	0.0060(-0.0004,0.0123)0.065
	Q3 : 0.01700-0.17900ng/ml	-0.0090(-0.0164,-0.0015)0.018	-0.0037(-0.0101,0.0026)0.250	-0.0045(-0.0109,0.0019)0.164
Trochanter BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0070(-0.0050,0.0189)0.253	0.0037(-0.0051,0.0124)0.409	0.0040(-0.0045,0.0127)0.371
	Q3 : 0.01700-0.17900ng/ml	-0.0116(-0.0234,0.0005)0.059	-0.0053(-0.0140,0.0035)0.239	-0.0057(-0.0145,0.0030)0.198
Intertrochanter BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0032(-0.0035,0.0100)0.349	0.0054(-0.0001,0.0110)0.055	0.0058(-0.0003,0.0114)0.039
	Q3 : 0.01700-0.17900ng/ml	-0.0070(-0.0138,-0.0002)0.043	-0.0016(-0.0072,0.0040)0.566	-0.0021(-0.0077,0.0034)0.445
Intertrochanter BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0038(-0.0078,0.0154)0.521	0.0021(-0.0057,0.0099)0.596	0.0024(-0.0054,0.0102)0.547
	Q3 : 0.01700-0.17900ng/ml	-0.0151(-0.0267,-0.0036)0.010	-0.0064(-0.0143,0.0014)0.107	-0.0068(-0.0147,0.0010)0.086
Wards triangle BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	-0.0116(-0.0241,0.0009)0.069	0.0059(-0.0037,0.0155)0.228	0.0068(-0.0027,0.0163)0.162
	Q3 : 0.01700-0.17900ng/ml	-0.0184(-0.0301,-0.0059)0.004	-0.0002(-0.0098,0.0094)0.962	-0.0017(-0.0113,0.0078)0.725
Wards triangle BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	-0.0117(-0.0253,0.0019)0.091	0.0073(-0.0032,0.0179)0.172	0.0083(-0.0022,0.0188)0.120
	Q3 : 0.01700-0.17900ng/ml	-0.0209(-0.0345,-0.0074)0.002	-0.0023(-0.0129,0.0083)0.666	-0.0040(-0.0145,0.0065)0.457

Model 1: no covariates were adjusted; Model 2: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI were adjusted; Model 3: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI, smoking, alcohol consumption, arthritis, COPD, history of osteoporosis, thyroid problems were adjusted.

\*Logarithmic conversion of all BMD/BMC data.

172

173

**Table2: The relationship between blood chloroform and BMD/BMC in the spine**

	Chloroform (ng/mL)	Model1 β(95%CI) value	Model2 β(95%CI) P value	Model3 β(95%CI) P value
Total spine BMD(g/cm2)*	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0018(-0.0045,0.0082)0.572	0.0023(-0.0037,0.0082)0.456	0.0024(-0.0035,0.0083)0.424
	Q3 : 0.01700-0.17900ng/ml	-0.0054(-0.0118,0.0009)0.093	-0.0049(-0.0109,0.0010)0.106	-0.0050(-0.0109,0.0010)0.100
Total spine BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0036(-0.0062,0.0135)0.471	0.0027(-0.0059,0.0113)0.535	0.0029(-0.0057,0.0114)0.510
	Q3 : 0.01700-0.17900ng/ml	-0.0110(-0.0208,-0.0012)0.028	-0.0080(-0.0166,0.0006)0.068	-0.0080(-0.0165,0.0006)0.068
L1 BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0039(-0.0030,0.0108)0.266	0.0040(-0.0023,0.0103)0.211	0.0042(-0.0021,0.0104)0.194
	Q3 : 0.01700-0.17900ng/ml	-0.0014(-0.0083,0.0055)0.695	-0.0002(-0.0066,0.0061)0.941	-0.0002(-0.0069,0.0065)0.951
L1 BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0083(-0.0026,0.0191)0.136	0.0053(-0.0038,0.0144)0.251	0.0054(-0.0036,0.0144)0.241
	Q3 : 0.01700-0.17900ng/ml	-0.0030(-0.0138,0.0079)0.592	-0.0001(-0.0092,0.0090)0.986	0.0002(-0.0089,0.0093)0.970
L2 BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0007(-0.0060,0.0073)0.839	0.0020(-0.0042,0.0081)0.533	0.0021(-0.0040,0.0082)0.498
	Q3 : 0.01700-0.17900ng/ml	-0.0062(-0.0128,0.0004)0.066	-0.0045(-0.0107,0.0017)0.155	-0.0046(-0.0107,0.0016)0.147
L2 BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0054(-0.0048,0.0157)0.297	0.0045(-0.0042,0.0133)0.310	0.0046(-0.0041,0.0133)0.297
	Q3 : 0.01700-0.17900ng/ml	-0.0118(-0.0220,-0.0016)0.023	-0.0078(-0.0166,0.0010)0.082	-0.0076(-0.0164,0.0011)0.086
L3 BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0012(-0.0053,0.0077)0.719	0.0017(-0.0045,0.0079)0.595	0.0018(-0.0043,0.0079)0.566
	Q3 : 0.01700-0.17900ng/ml	-0.0050(-0.0115,0.0015)0.130	-0.005(-0.0113,0.0011)0.105	-0.0052(-0.0113,0.0010)0.101
L3 BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.005517(-0.0042,0.0153)0.267	0.0048(-0.0039,0.0135)0.281	0.0049(-0.0037,0.0136)0.263
	Q3 : 0.01700-0.17900ng/ml	-0.0116(-0.0213,-0.0019)0.020	-0.0091(-0.0178,-0.0004)0.040	-0.0092(-0.0178,-0.0005)0.038
L4 BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0023(-0.0043,0.0088)0.494	0.0020(-0.0042,0.0083)0.527	0.0022(-0.0040,0.0084)0.489
	Q3 : 0.01700-0.17900ng/ml	-0.0073(-0.0138,-0.0008)0.028	-0.0078(-0.0140,-0.0015)0.015	-0.0079(-0.0141,-0.0017)0.013
L4 BMC (g)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0015(-0.0083,0.0114)0.758	0.0004(-0.0085,0.0093)0.926	0.0006(-0.0082,0.0095)0.889
	Q3 : 0.01700-0.17900ng/ml	-0.0145(-0.0243,-0.0047)0.004	-0.0128(-0.0217,-0.0039)0.005	-0.0129(-0.0218,-0.0041)0.004

Model 1: no covariates were adjusted; Model 2: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI were adjusted; Model 3: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI, smoking, alcohol consumption, arthritis, COPD, history of osteoporosis, thyroid problems were adjusted.

\*Logarithmic conversion of all BMD/BMC data.

174

175

176

## Connection between chloroform and BMC

177

Detailed results are presented in Tables 1-2 and S2. Weighted univariate and multiple

178 linear regression analyses are illustrated in Tables 1-2. In model 1, blood chloroform  
179 levels were categorized by tertile, except for rotor BMC ( $\beta$  -0.0023; 95% CI -0.0066,  
180 0.0021), and L1 BMC ( $\beta$  -0.0004; 95% CI -0.0058, 0.0049). There was a negative  
181 correlation between increased blood chloroform concentrations and BMC at several  
182 sites, including total femoral BMC, femoral neck BMC, Intertrochanter BMC, Ward's  
183 triangle BMC, total spine BMC, L2 BMC, L3 BMC, and L4 BMC. Additionally,  
184 increased blood chloroform concentrations in the femur and spine were negatively  
185 correlated with BMC ( $P < 0.05$ ). The L3 BMC and L4 BMC were negatively correlated  
186 with blood chloroform levels after adjusting for some covariates (model 2). Finally, in  
187 model 3, L3 BMC and L4 BMC decreased with increasing blood chloroform  
188 concentration.

### 189 **Subgroup analysis**

190 The findings of subgroup analyses adjusted for associated covariates are shown in  
191 **Tables 3-5**. According to the Multiple regression analysis in the femoral area, the  
192 femoral neck BMC blood chloroform level decreased in the male gender ( $\beta$  -0.0059; 95  
193 % CI -0.0115, -0.0002;  $P < 0.05$ ). According to the analysis by race as a subgroup, the  
194 femoral neck BMD/BMC in Non-Hispanic White and other Race-Including Multi-  
195 Racial subjects exhibited a negative correlation with blood chloroform concentration  
196 ( $P < 0.05$ ). In contrast, no meaningful correlation between blood chloroform and BMD  
197 or BMC was observed in Mexican-American, Non-Hispanic Black, and Other Hispanic  
198 subjects. A negative correlation between blood chloroform and femoral neck  
199 BMD/BMC was revealed by the results stratified by age but only in the 65-80 years-

200 old participants ( $\beta$  -0.0100; 95% CI -0.0186, -0.0014;  $P < 0.05$ ); ( $\beta$  -0.0144; 95% CI -  
 201 0.0234, -0.0054;  $P < 0.05$ ).

**Table3 Association of blood chloroform with femur neck BMD/BMC, stratified by sex, race/ethnicity and age.**

	femur neckBMD (g/cm <sup>2</sup> )	$\beta$ (95%CI) value	femur neck (g)	$\beta$ (95%CI) value
Subgroup analysis stratified by gender				
male	-0.0020(-0.0073,0.0033)	0.454	-0.0045(-0.0100,0.0011)	0.114
female	-0.0046(-0.0100,0.0008)	0.094	-0.0059(-0.0115,-0.0002)	0.041
Subgroup analysis stratified by race/ethnicity				
Mexican American	-0.0020(-0.0098,0.0058)	0.617	-0.0041(-0.0139,0.0058)	0.416
Other Hispanic	-0.0052(-0.0163,0.0060)	0.361	-0.0079(-0.0215,0.0057)	0.253
Non-Hispanic White	-0.0075(-0.0135,-0.0015)	0.015	-0.0086(-0.0158,-0.0015)	0.018
Non-Hispanic Black	-0.0086(-0.0178,0.0006)	0.0664	-0.0104(-0.0211,0.0003)	0.056
Other Race—Including Multi-Racial	-0.0119(-0.0242,0.0003)	0.056	-0.0171(-0.0324,-0.0018)	0.028
Subgroup analysis stratified by age				
18-45	0.0034(-0.0010,0.0078)	0.126	0.0018(-0.0031,0.0066)	0.478
45-65	0.0016(-0.0032,0.0064)	0.517	-0.0006(-0.0058,0.0047)	0.832
65-80	-0.0100(-0.0186,-0.0014)	0.022	-0.0144(-0.0234,-0.0054)	0.002

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

202

203

**Table4 Association of blood chloroform with wards triangle BMD/BMC, stratified by sex, race/ethnicity and age.**

	Wards triangle BMD (g/cm <sup>2</sup> )	$\beta$ (95%CI) value	Wards triangleBMC (g)	$\beta$ (95%CI) value
Subgroup analysis stratified by gender				
male	-0.0020(-0.0110,0.0069)	0.658	-0.0023(-0.0118,0.0072)	0.634
female	-0.0118(-0.0204,-0.0032)	0.007	-0.0144(-0.0239,-0.0049)	0.003
Subgroup analysis stratified by race/ethnicity				
Mexican American	-0.0024(-0.0148,0.0100)	0.703	-0.0036(-0.0172,0.0100)	0.605
Other Hispanic	-0.0068(-0.0244,0.0109)	0.451	-0.0090(-0.0281,0.0102)	0.358
Non-Hispanic White	-0.0124(-0.0224,-0.0024)	0.015	-0.0136(-0.0244,-0.0027)	0.015
Non-Hispanic Black	-0.0133(-0.0286,0.0021)	0.091	-0.0153(-0.0318,0.0012)	0.070
Other Race—Including Multi-Racial	-0.0103(-0.0293,0.0087)	0.289	-0.0118(-0.0324,0.0089)	0.2639
Subgroup analysis stratified by age				
18-45	0.0037(-0.0025,0.0099)	0.241	0.0018(-0.0052,0.0088)	0.616
45-65	0.0052(-0.0023,0.0128)	0.175	0.0049(-0.0034,0.0131)	0.251
65-80	-0.0065(-0.0211,0.0081)	0.381	-0.0060(-0.0216,0.0095)	0.447

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

204

205

**Table5 Association of blood chloroform with L4 BMD/BMC, stratified by sex, race/ethnicity and age.**

	L4BMD (g/cm <sup>2</sup> )	$\beta$ (95%CI) value	L4BMC (g)	$\beta$ (95%CI) value
Subgroup analysis stratified by gender				
male	-0.0012(-0.0057,0.0033)	0.600	-0.0034(-0.0098,0.0030)	0.297
female	-0.0044(-0.0090,0.0002)	0.060	-0.009(-0.0149,-0.0022)	0.009
Subgroup analysis stratified by race/ethnicity				
Mexican American	-0.0055(-0.0125,0.0015)	0.124	-0.0107(-0.0217,0.0002)	0.054
Other Hispanic	-0.0028(-0.0124,0.0067)	0.560	-0.0058(-0.0204,0.0088)	0.437
Non-Hispanic White	-0.0044(-0.0093,0.0005)	0.082	-0.0078(-0.0152,-0.0005)	0.037
Non-Hispanic Black	-0.0066(-0.0142,0.0011)	0.095	-0.0109(-0.0223,0.0004)	0.059
Other Race—Including Multi-Racial	-0.0057(-0.0168,0.0054)	0.313	-0.0113(-0.0286,0.0059)	0.196
Subgroup analysis stratified by age				
18-45	0.0001(-0.0037,0.0039)	0.957	-0.0014(-0.0071,0.0043)	0.625
45-65	-0.0037(-0.0088,0.0014)	0.156	-0.0073(-0.0145,-0.0001)	0.047
65-80	-0.0072(-0.0162,0.0018)	0.119	-0.0154(-0.0282,-0.0026)	0.018

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

206

207 Results of the multiple regression analysis of Ward's triangle region revealed that

208 stratified by gender, female Ward's triangle BMD decreased while chloroform levels

209 increased and that female Ward's triangle BMC was negatively correlated with  
210 chloroform. According to the results stratified by race, blood chloroform concentration  
211 was negatively correlated with BMD/BMC except for Hispanic white subjects ( $\beta$  -  
212 0.0124; 95%CI -0.0224, -0.0024;  $P < 0.05$ ); ( $\beta$  -0.0136; 95% CI -0.0244, -0.0027;  
213  $P < 0.05$ ). Additionally, although BMC was not statistically significant, chloroform  
214 concentrations were correlated with BMD in Mexican-American, Other Hispanic, Non-  
215 Hispanic Black and Other Race-Including Multi-Racial participants. The results  
216 stratified by age revealed no statistically significant association between chloroform  
217 concentrations and BMD and BMC at all femoral sites in all age groups.

218 Female L4 BMC decreased with increasing blood chloroform in the spinal region  
219 following stratification by sex ( $\beta$  -0.009; 95% CI -0.0149, -0.0022;  $P < 0.01$ ). When  
220 stratified by race, we discovered a significant correlation between Non-Hispanic White  
221 BMC and blood chloroform ( $\beta$  -0.0078; 95% CI -0.0152, -0.0005;  $P < 0.05$ ).  
222 Additionally, there was a significant negative correlation between BMC and  
223 chloroform in the 45-65 and 65-80 age groups when age was used as a stratification  
224 factor ( $\beta$  -0.0073; 95% CI -0.0145, -0.0001;  $P < 0.05$ ); ( $\beta$  -0.0154; 95% CI -0.0282, -  
225 0.0026;  $P < 0.05$ ).

## 226 **Discussion**

227 Osteoporosis is a degenerative bone disease that increases the risk of fracture [20]. With  
228 the aging population, osteoporosis is becoming a major public health concern  
229 worldwide [21,22]. The current era of rapid global economic development  
230 characterized by various industrial processes, including increased production of

231 automobiles, tobacco, cleaning products, building materials, and other household  
232 products, has made VOCs more common in the human environment [23,24,25,26,27].  
233 Several studies have demonstrated that some VOCs, such as Perfluoro and  
234 Polyfluoroalkyl Substances (PFAS), Urinary Polycyclic Aromatic Hydrocarbons  
235 (UPAHs), trichlorophenol, and many other organics are negatively associated with  
236 BMD/BMC levels at specific sites in the human body [28,29,30]. The safety of urban  
237 centralized water supply largely relies on water disinfection as it kills pathogens and  
238 prevents waterborne infectious diseases [31]. However, water Disinfection Byproducts  
239 (DBPs) mostly contain certain VOCs, including chloroform, bromine,  
240 dibromochloromethane, and dichlorobromomethane, with chloroform presence being  
241 exceptionally high in these DBPs [32]. A survey specifically focused on chloroform  
242 was conducted in China to evaluate the health risks associated with municipal water  
243 supply. It analyzed the distribution pattern and seasonal chloroform variation  
244 characteristics in the municipal water supply in Xi'an and the average daily chloroform  
245 exposure dose. According to the results, the average daily exposure dose of chloroform  
246 in the Xi'an municipal water supply was  $7.39 \times 10^{-4}$  mg/(kg\*d), with drinking water  
247 consumption as the leading source for the non-carcinogenic risk of chloroform [33].  
248 Another survey found that the carcinogenic risk of ten contaminants in city drinking  
249 water, including chloroform, exceeded the acceptable level [34]. All these studies  
250 indicate that chloroform could potentially harm human health, but no conclusive study  
251 has proven the dangers of chloroform exposure to public safety. Although some studies  
252 have associated chloroform co-exposure with bone health indicators [15], no link with

253 BMD has been reported. In our study, we hypothesize that there could be a connection  
254 between blood chloroform and BMD/BMC. After adjusting for confounders, we  
255 discovered a negative correlation between BMD/BMC and blood chloroform in L3  
256 BMC and L4 BMD/BMC. Our analysis revealed a negative association between  
257 chloroform and femoral neck BMD in participants aged 65-80 years and Non-Hispanic  
258 White subjects, as well as Ward's triangle BMD in women and Non-Hispanic White  
259 subjects. For BMC, a negative correlation was found between blood chloroform and  
260 femoral neck BMC, Non-Hispanic White and Other Race-Including Multi-Racial  
261 subjects femoral neck BMC, female Ward's triangular BMC, Ward's Triangular BMC  
262 of female Non-Hispanic White and 65-80 years old subjects, Female L4 and Non-  
263 Hispanic White Subjects BMC, and L4 BMC of 45-65 years and 65-80 years old  
264 subjects.

265 Multiple linear regression analysis and analysis within the Asian group revealed  
266 the relationship between blood chloroform and BMD/BMC in most areas of the femur  
267 and spine before adjusting for confounding factors. However, after adjusting for  
268 confounding variables, it was discovered that the correlation between blood chloroform  
269 and femoral BMD/BMC was not as strong. This finding implies that the relationship  
270 between blood chloroform and femoral BMD/BMC is largely influenced by age, gender,  
271 and race. On the one hand, this phenomenon may be attributed to femur and lumbar  
272 spine structures, which theoretically have the most substantial BMD changes in  
273 postmenopausal women with a higher proportion of cancellous bone [35, 36, 37, and  
274 38]. On the other hand, it could be attributed to the sample population's old age ( $48.8 \pm$

275 16.8 years), where hormonal drugs used by some older individuals exert a greater  
276 influence on femoral BMD/BMC than on lumbar spine BMD/BMC, making blood  
277 chloroform less likely to be associated with femoral BMD/BMC [39]. Furthermore,  
278 after adjusting for relevant covariates, stratified analysis by age, sex, and race revealed  
279 that chloroform concentration was negatively correlated with BMC at most sites. Blood  
280 chloroform concentration at L4 was significantly negatively correlated with BMC in  
281 women in the subgroup analysis. Contrastingly, no correlation between chloroform  
282 concentration and femoral or spinal BMC was observed in men, implying that blood  
283 chloroform levels may have some predictive value for bone mass in women. This  
284 phenomenon may be attributed to the sample population's older age ( $48.8 \pm 16.8$  years)  
285 and the substantial decline in sex hormone levels in postmenopausal women resulting  
286 in lower femoral BMD quantity. Men, on the other hand, showed no such specific  
287 changes. We hypothesized that the varying sex hormone levels might influence the  
288 femoral neck, Ward's triangle, or L4 BMC differently. Furthermore, the association  
289 between blood chloroform and femoral and spinal BMC was closer than that of BMD,  
290 which may be explained by the significant variations in the bone area resulting from  
291 individual differences.

292 Both BMD and BMC have been shown by studies to be significant osteoporosis  
293 indicators and to play a critical role in osteoporotic fracture development [40]. Our  
294 study revealed a negative correlation between blood chloroform in some spine regions  
295 and BMD/BMC. Chloroform is used as a solvent to soften material during endodontic  
296 treatment, and case studies revealed that during the patients' endodontic retreatment



297 visit, chloroform was extruded through the perforation into the periodontal ligament  
298 space, resulting in necrosis of the tooth-supporting bone [41]. Our findings on the  
299 negative effect of chloroform on bone loss are consistent with another research which  
300 discovered that organochlorine contaminants-exposure could impact fertility, the  
301 menstrual cycle, and other aspects of the human reproductive system [42,43]. In a  
302 pharmaceutical company, female personnel exposed to a mixture of organic solvents  
303 (including chloroform) exhibited higher Thyroid-Stimulating Hormone (TSH) levels  
304 than the non-exposed group, with a significant correlation between chloroform and  
305 TSH levels [44]. According to some clinical studies, a positive correlation exists  
306 between TSH and femoral and spinal BMD in early postmenopausal women [45].  
307 Consequently, we speculate that chloroform may have a positive association with  
308 BMD/BMC mediated by hormones *in vivo*, and this hypothesis is supported by the "V"-  
309 shaped correlation between chloroform, and BMD/BMC discovered in our study (**Fig2-**  
310 **3**). Additionally, we hope to find the link between chloroform and bone metabolism  
311 through preliminary data analysis and further basic research. In this regard, our group  
312 has already started collecting environmental exposure samples and establishing a  
313 sample bank. (**Fig2-3:Restricted cubic spline plots between chloroform and femoral**  
314 **neck BMC and chloroform and L4 BMC** )

315 With this cross-sectional research, we plan to further explore the effect of  
316 chloroform exposure on BMD/BMC. Herein, we used raw data on blood chloroform  
317 and femoral and spinal BMD/BMC from adults selected from NHANES in 2009-2010,  
318 2013-2014, and 2017-2020 to perform a Restricted Cubic Splines (RCS) analysis of the

319 relationship between chloroform and BMD/BMC. The non-linear connection between  
320 blood chloroform and spinal BMD/BMC revealed a "V" shaped correlation and a  
321 statistically significant association between chloroform levels within the 0-0.02 ng/ml  
322 range and spinal BMD/BMC (**Figure2-3**). According to the literature review in some  
323 studies, chloroform harms BMD/BMC. Contrastingly, some studies suggest that  
324 chloroform may have a positive association with BMD/BMC. However, no specific  
325 reference in the literature demonstrates a clear connection between chloroform and  
326 BMD/BMC; thus, more research is required to determine the optimal level of  
327 chloroform exposure in relation to BMD/BMC levels. The above findings imply that  
328 exposure to VOCs such as chloroform remains a major public health concern.  
329 Disinfection byproducts are ubiquitous, and people (particularly older adults) with  
330 prolonged exposure to the chloroform from these products must be especially aware of  
331 their long-term risks.

## 332 **Limitation**

333 Our study had several limitations. First, the data used in this investigation was obtained  
334 from NHANES, and therefore it was difficult to establish the exact timing between  
335 chloroform exposure and changes in BMD. Consequently, we could only develop  
336 correlations but not causality at this point. More research through prospective studies  
337 is therefore required to investigate this further. Second, our data on subjects were  
338 primarily from a single time point, making it difficult to determine the association  
339 between chloroform and BMD/BMC over time, potentially leading to bias in  
340 classifying specific populations. Third, some data were from self-reported

341 questionnaires, which may have resulted in recall or misclassification bias. Fourth,  
342 missing whole-body skeletal BMD/BMC data impeded a comprehensive examination  
343 of the chloroform and BMD/BMC correlation. Finally, the residual confounding  
344 problem persisted despite employing multivariate adjustment techniques. We are  
345 developing a cohort of VOC exposure (including chloroform) in our city and expect  
346 that more convincing evidence elucidating the link between chloroform and  
347 BMD/BMC will soon be available.

## 348 **Conclusion**

349 After adjustment for confounders, we established a "V" shaped correlation between  
350 blood chloroform and femoral spine BMD/ BMC, with a negative correlation at 0-0.02  
351 ng/ml ( $p < 0.05$ ), especially for L4 BMC. Our research provides epidemiological  
352 evidence for further investigation into the correlation between chloroform and BMD/  
353 BMC.

## 354 **Acknowledgements**

355 This thesis would not have been possible without the consistent and valuable reference  
356 materials that I received from my supervisor whose insightful guidance and enthusiastic  
357 encouragement in the course of my shaping this thesis definitely gains my deepest  
358 gratitude.

## 359 **References**

360 1. Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop Relat Res. 2000  
361 Mar;(372):139-50.10. doi:1097/00003086-200003000-00016

- 362 2. Farrah Z, Jawad AS. Optimising the management of osteoporosis. *Clinical*  
363 *medicine* (London, England). 2020 Sep;20(5): e196-e201. doi:  
364 10.7861/clinmed.2020-0131
- 365 3. Zhang R, Huang Q, Su G, Wei M, Cui Y, Zhou H, Song W, Di D, Liu J, Wang Q.  
366 Association between multiple vitamins and bone mineral density: a cross-sectional  
367 and population-based research in the NHANES from 2005 to 2006. *Population-*  
368 *based research in the NHANES from 2005 to 2006. BMC Musculoskelet Disord.*  
369 2023 Feb 10;24(1):113. doi: 10.1186/s12891-023-06202-6
- 370 4. Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The  
371 epidemiology of osteoporosis. *Br Med Bull.* 2020 May 15;133(1):105-117.  
372 doi:10.1093/bmb/ldaa005
- 373 5. Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley  
374 JA, Bauer DC, Black DM; FNIH Bone Quality Project. Change in Bone Density  
375 and Reduction in Fracture Risk: A Meta-Regression of Published Trials. *J Bone*  
376 *Miner Res.* 2019 Apr;34(4):632-642. doi:10.1002/jbmr.3641
- 377 6. Levin VA, Jiang X, Kagan R. Estrogen Therapy for osteoporosis in the modern  
378 era. *Osteoporos Int.* 2018;29(5):1049-1055. doi: 10.1007/s00198-018-4414-z
- 379 7. Chen LR, Hou PH, Chen KH. Nutritional support and physical modalities for  
380 people with osteoporosis: current opinion. *Nutrients.* 2019;11(12): 15. doi:  
381 10.3390/nu11122848
- 382 8. Li Adela Jing, Pal Vineet Kumar, and Kannan Kurunthachalam. A review of  
383 environmental occurrence, toxicity, biotransformation and biomonitoring of

- 384 volatile organic compounds." 3.(2021):91-116.
- 385 9. McGraw KE, Riggs DW, Rai S, Navas-Acien A, Xie Z, Lorkiewicz P, et al.  
386 Exposure to volatile organic compounds - acrolein, 1,3-butanadiene, and  
387 crotonaldehyde - is associated with vascular dysfunction. *environ res.* (2021)  
388 196:110903. doi:10.1016/j.envres.2021.110903
- 389 10. Wei C, Chen Y, Yang Y, Ni D, Huang Y, Wang M, Yang X, Chen Z. Assessing  
390 Volatile Organic Compounds Exposure and Prostate-specific Antigen: National  
391 Health and Nutrition Examination Survey, 2001-2010. *Front Public Health.* 2022  
392 Jul 29; 10: 957069. doi:10.3389/fpubh.2022.957069
- 393 11. National Toxicology Program. NTP toxicology and carcinogenesis studies of  
394 methyl bromide (CAS: 74-83-9) in B6C3F1 mice (inhalation studies). *Natl Toxicol*  
395 *Program Tech Rep Ser.* 1992 Mar; 385: 1-212.
- 396 12. Smith JT, Schneider AD, Katchko KM, Yun C, Hsu EL. Environmental factors  
397 impacting bone-relevant chemokines. *Front Endocrinol (Lausanne).* 2017 Feb 14;  
398 8: 22. doi: 10.3389/fendo.2017.00022
- 399 13. Lehmann I, Roder-Stolinski C, Nieber K, Fischader G. In vitro models for the  
400 assessment of inflammatory and immuno-modulatory effects of the volatile  
401 organic compound chlorobenzene. *Exp Toxicol Pathol* (2008) 60(2–3):185–93. doi:  
402 10.1016/j.etp.2008.01.009
- 403 14. Fischader G, Roder-Stolinski C, Wichmann G, Nieber K, Lehmann I. Release of  
404 MCP-1 and IL-8 from lung epithelial cells exposed to volatile organic compounds.  
405 *Toxicol In Vitro* (2008) 22(2):359–66. doi: 10.1016/j.tiv.2007.09.015

- 406 15. Zhou HL, Su GH, Zhang RY, Di DS, Wang Q. Association of volatile organic  
407 compounds co-exposure with bone health indicators and potential mediators.  
408 *Chemosphere*. 2022 Dec;308(Pt 1):136208. doi:  
409 10.1016/j.chemosphere.2022.136208
- 410 16. Batterman S, Su FC, Li S, Mukherjee B, Jia C; HEI Health Review Committee.  
411 Personal exposure to mixtures of volatile organic compounds: modeling and res  
412 health eff Inst. 2014 Jun;(181):3-63.
- 413 17. Toxicity of Chloroform. *Prescrire Int*. 1998 Oct;7(37):149.
- 414 18. Cui Y, Zhou HL, Wei MH, Song WJ, Di DS, Zhang RY, et al. Multiple vitamin  
415 co-exposure and mortality risk: a prospective research. *Clin Nutr*. 2022; 41(2): 337  
416 -347. doi: 10.1016/j.clnu.2021.12.010
- 417 19. Lee S, Ko K, Shin S, Park HS, Hong N, Rhee Y. Adipopenia is associated with  
418 osteoporosis in community-dwelling non-underweight adults independent of  
419 sarcopenia. *Arch Osteoporos*. 2023 Mar 22;18(1): 44. doi:10.1007/s11657-023-  
420 01233-x
- 421 20. Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies  
422 for osteoporosis. *Pharmacol Ther*. (2022) 237:108168. doi:  
423 10.1016/j.pharmthera.2022.108168
- 424 21. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al.  
425 Osteoporosis in the European Union: medical management, epidemiology and  
426 economic burden. A report prepared in collaboration with the international  
427 osteoporosis foundation (IOF) and the European Federation of Pharmaceutical

- 428 Industry Associations (EFPIA). *Arch Osteoporos.* (2013) 8:136. doi:  
429 10.1007/s11657-013-0136-1
- 430 22. Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et  
431 al. The global prevalence of osteoporosis in the world: a comprehensive systematic  
432 review and meta-analysis. *J Orthop Surg Res.* 2021 Oct 17;16(1):609. doi:  
433 10.1186/s13018-021-02772-0
- 434 23. Konkle SL, Zierold KM, Taylor KC, Riggs DW, Bhatnagar A. National secular  
435 trends in ambient air volatile organic compound levels and biomarkers of exposure  
436 in the United States. *Environ Res.* (2020) 182:108991. doi:10.1016/j.envres.  
437 2019.108991
- 438 24. Jain RB. Detection Rates, Trends in and factors affecting observed levels of  
439 selected volatile organic compounds in blood among us adolescents and adults.  
440 *Environ Toxicol Pharmacol.*(2017) 56:21-8.doi:10.1016/j.etap.2017.08.031
- 441 25. Jain RB. Distributions of selected urinary metabolites of volatile organic  
442 compounds by age, gender, race/ethnicity, and smoking status in a representative  
443 sample of US adults. *Environ Toxicol Pharmacol.* (2015) 40: 471-9.  
444 doi:10.1016/j.etap.2015.07.018
- 445 26. Liu B, Jia C. Effects of exposure to mixed volatile organic compounds on the  
446 neurobehavioral test performance in a cross-sectional research of US adults. *Int J*  
447 *Environ Health Res.* (2015) 25: 349-63. doi:10.1080/09603123.2014.945514
- 448 27. Su FC, Jia C, Batterman S. Extreme value analyses of VOC exposures and risks: a  
449 comparison of riopa and NHANES datasets. *atmospheric environ.* (2012) 62:97.

- 450 106. doi: 10.1016/j.atmosenv. 2012.06.038
- 451 28. Yan Z, Xiong X, Tao J, Wang S. Association of bone mineral density with  
452 trichlorophenol: a population-based research. BMC musculoskelet disord. 2023  
453 Mar 17. 24(1): 202. doi:10.1186/s12891-023-06323-y
- 454 29. Kirk AB, DeStefano A, Martin A, Kirk KC, Martin CF. A new interpretation of  
455 relative importance on an analysis of per and polyfluorinated alkyl substances  
456 (PFAS) exposures on bone mineral density. Int J Environ Res Public Health. 2023  
457 Mar 3; 20 (5): 4539. doi:10.3390/ijerph20054539
- 458 30. Yang R, Chen Z, Hu Y. Associations of urinary polycyclic aromatic hydrocarbons  
459 with bone mineral density at specific body sites in U.S. Adults, National Health  
460 and Nutrition Examination Survey 2001 to 2004. Endocr Pract. 2022 Sep; 28(9):  
461 867-874.10.1016/j.eprac.2022.06.008
- 462 31. Yang KD. Environmental hygiene (M). Beijing: people's medical publishing house,  
463 2017.
- 464 32. Xu H, Cai J. Determination and risk assessment of disinfection by- products in  
465 drinking water of S city(J). Water & Wastewater Engineering, 2020,56(9):37-40.
- 466 33. Zhao GP, Zou KT, Xu Q, Liu RX, Luo XH, Guan R. Distribution characteristics  
467 and multi - pathways health risk assessment of trichloromethane in municipal water  
468 of Xi'an.Modern Preventive Medicine(J). 2023,50(4):611-617.
- 469 34. Han JY,Ye BX,Zhang L. Health Risk Assessment of 10 pollutants in a city's  
470 drinking water.Journal of environmental hygiene Jun(J).2019,9( 3):203-209.
- 471 35. Wang C, Zhu Y, Long H, Ou M, Zhao S. Connection between blood manganese



- 472 and bone mineral density and bone mineral content in adults: a population-based  
473 cross-sectional research. *PLoS One*. 2022 Oct 21; 17(10): e0276551.  
474 doi:10.1371/journal.pone.0276551
- 475 36. Mosekilde L, Danielsen CC, Gasser J. The effect on vertebral bone mass and  
476 strength of long term treatment with antiresorptive agents (estrogen and calcitonin),  
477 human parathyroid hormone-(1-38), and combination therapy, assessed in aged  
478 ovariectomized rats. *Endocrinology*. 1994 May;134(5):2126-34. doi:  
479 10.1210/endo.134.5.8156913.
- 480 37. Liu J, Wang W, Tong QJ, et al. A comparative research of dual-energy X-ray bone  
481 densitometry (DXA) and A comparative research of bone density measurement by  
482 dual-energy X-ray bone densitometry (DXA) and quantitative CT (QCT)(J).  
483 *Journal of Clinical Radiology*.2007, 26(5): 504- 507.
- 484 38. Yamauchi H, Kushida K, Yamazaki K, et al. Assessment of spine bone mineral  
485 density in ovariectomized rats using DXA(J). *J Bone Miner Res*, 1995, 10(7):  
486 1033- 1036. doi: 10.1002/jbmr.5650100707
- 487 39. Yin X, Zhao S, Xiang N, Chen J, Xu J, Zhang Y. Efficacy of Bushen Jiangu therapy  
488 in the treatment of glucocorticoid-induced osteoporosis: A systematic review and  
489 meta-analysis of randomized controlled trials. *Medicine (Baltimore)*. 2023 Mar  
490 17;102(11): e33278. doi: 10.1097/MD.00000000000033278
- 491 40. Deng HW, Xu FH, Davies KM, Heaney R, Recker RR. Differences in Bone  
492 Mineral Density, Bone Mineral Content, and Bone Areal Size in Fracturing and  
493 Non-fracturing Women, and Their Interconnections at the Spine and Hip.

- 494 Fracturing Women, and Their Interconnections at the Spine and Hip. *Journal of*  
495 *bone and mineral metabolism*. 2002; 20(6): 358-66.doi:10.1007/s007740200052
- 496 41. Mohammadzadeh Akhlaghi N, Baradaran Mohajeri L, Fazlyab M. Tissue Necrosis  
497 due to Chloroform: a Case Report. *Iran Endod J*. 2013 Fall;8(4):208-9.
- 498 42. Bonde JP, Toft G, Rylander L, Rignell-Hydbom A, Giwercman A, Spano M,  
499 Manicardi GC, Bizzaro D, Ludwicki JK, Zvyezday V, Bonefeld-Jørgensen EC,  
500 Pedersen HS, Jönsson BA, Thulstrup AM; INUENDO. Fertility and markers of  
501 male reproductive function in Inuit and European populations spanning large  
502 contrasts in blood levels of persistent organochlorines. *Environ Health Perspect*.  
503 2008 Mar;116(3):269-77. doi: 10.1289/ehp.10700
- 504 43. Figa-Talamanca I. Occupational risk factors and reproductive health of women.  
505 *Occup Med (Lond)* 2006; 56: 521–531. doi: 10.1093/occmed/kql114
- 506 44. Hassani S, Namvar M, Ghoreishvandi M, Attarchi M, Golabadi M, Seyedmehdi  
507 SM, Khodarahmian M. Menstrual disturbances and hormonal changes in women  
508 workers exposed to a mixture of organic solvents in a pharmaceutical company.  
509 *Med J Islam Repub Iran*. 2014 Dec 27; 28:156.
- 510 45. Begić A, Begić A, Arnautović-Halimić A. Influence of thyroid hormones on bone  
511 density. *Med Glas (Zenica)*. 2020 Feb 1;17(1):35-40. doi: 10.17392/1056-20

## 512 **Supporting information**

### 513 **S1 Table Related demographic characteristics of participants included in**


514 **NHANES from 2009 to 2010 and 2013 to 2014 and 2017-2020.** Means with

515 standard deviation (SD) were used for continuous characteristic variables and


516 categorical variables were expressed as frequencies. Differences in categorical  
517 variables between exposed groups were analyzed by Kruskal Wallis test or Mann  
518 Whitney test. Spearman correlation analysis was used to analyze the differences of  
519 continuous variables between groups.

520 (EXCEL)


521 **S2 Table Blood chloroform and area, BMC, and BMD based on chloroform**  
522 **tristimulus.** Data are expressed as means (standard deviation, SD). BMC, bone mineral  
523 content, BMD, bone mineral density, Area (cm<sup>2</sup>), BMC (g), BMD (g/cm<sup>2</sup>). (EXCEL)



Figure



Figure



Figure